Atom Investors LP Buys Shares of 10,196 Cardlytics, Inc. (NASDAQ:CDLX)

Atom Investors LP purchased a new position in shares of Cardlytics, Inc. (NASDAQ:CDLXFree Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 10,196 shares of the company’s stock, valued at approximately $33,000.

A number of other large investors have also made changes to their positions in the business. BNP Paribas Financial Markets grew its stake in Cardlytics by 32.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 19,745 shares of the company’s stock worth $63,000 after buying an additional 4,796 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Cardlytics during the third quarter worth about $153,000. Charles Schwab Investment Management Inc. increased its holdings in shares of Cardlytics by 3.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,343 shares of the company’s stock valued at $1,249,000 after acquiring an additional 11,388 shares in the last quarter. Intech Investment Management LLC purchased a new position in shares of Cardlytics in the 3rd quarter valued at approximately $47,000. Finally, Check Capital Management Inc. CA boosted its stake in Cardlytics by 10.4% in the 3rd quarter. Check Capital Management Inc. CA now owns 50,650 shares of the company’s stock worth $162,000 after purchasing an additional 4,775 shares in the last quarter. 68.10% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Cardlytics

In other news, CFO Alexis Desieno sold 25,118 shares of Cardlytics stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $3.43, for a total value of $86,154.74. Following the sale, the chief financial officer now owns 116,481 shares in the company, valued at $399,529.83. This trade represents a 17.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Amit Gupta sold 22,607 shares of the business’s stock in a transaction dated Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the sale, the chief executive officer now directly owns 178,519 shares of the company’s stock, valued at $687,298.15. This represents a 11.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,691 shares of company stock worth $237,767 in the last 90 days. Corporate insiders own 4.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and decreased their price target for the stock from $4.00 to $3.50 in a report on Thursday, August 15th. Evercore ISI assumed coverage on Cardlytics in a research note on Friday, October 11th. They set an “in-line” rating and a $4.00 price target on the stock. Lake Street Capital cut Cardlytics from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $18.00 to $5.00 in a research note on Thursday, August 8th. Northland Securities lowered Cardlytics from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $7.00 to $5.00 in a research report on Friday, August 16th. Finally, Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $6.92.

Get Our Latest Analysis on Cardlytics

Cardlytics Trading Up 0.3 %

Shares of NASDAQ:CDLX opened at $3.83 on Friday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 2.40. Cardlytics, Inc. has a 12-month low of $2.89 and a 12-month high of $20.52. The business has a 50 day moving average of $3.82 and a two-hundred day moving average of $5.65. The company has a market capitalization of $194.64 million, a PE ratio of -0.63 and a beta of 1.53.

Cardlytics (NASDAQ:CDLXGet Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative net margin of 93.55% and a negative return on equity of 110.67%. The firm had revenue of $67.06 million for the quarter, compared to the consensus estimate of $57.77 million. During the same period in the prior year, the firm posted ($0.26) earnings per share. The firm’s quarterly revenue was down 15.1% compared to the same quarter last year. As a group, analysts forecast that Cardlytics, Inc. will post -1.52 EPS for the current year.

About Cardlytics

(Free Report)

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.

Featured Articles

Want to see what other hedge funds are holding CDLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cardlytics, Inc. (NASDAQ:CDLXFree Report).

Institutional Ownership by Quarter for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.